Boston Scientific (BSX) closed the most recent trading day at $95.12, moving -0.14% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.13%. Meanwhile, ...

Boston Scientific BSX is slated to report first-quarter 2025 results on April 23, before market open. For first-quarter 2025, Boston Scientific projects adjusted earnings in the range of 66-68 cents ...

Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

Needham raised its rating on Boston Scientific (NYSE:BSX) from Hold to Buy, setting a new price target of $113, citing ...

Needham has upgraded Boston Scientific to a Buy, setting a new $113 target based on strengthened growth potential and less ...

Needham upgraded Boston Scientific Corp (NYSE:BSX) to “Buy”, saying competition from pulsed field ablation (PFA) rivals looks less intense for its key product than it was earlier feared, and citing ...

Needham upgraded Boston Scientific (BSX) to Buy from Hold with a $113 price target Needham’s latest electrophysiologist survey shows the ...

Elixir trails J&J’s Shockwave but has outpaced Bolt Medical to the European market with its mechanical IVL system.

Truist lowered the firm’s price target on Boston Scientific (BSX) to $113 from $120 and keeps a Buy rating on the shares as part of a broad ...

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular lithotripsy (IVL) system, positioning ...

The device is differentiated from other Shockwave products, and rival catheters from Abbott and Boston Scientific, because it ...

Boston Scientific (NYSE: BSX) announced on social media that it completed its previously announced acquisition of Bolt ...